Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Josef Geldwert

Podiatrist, Foot Surgery New York, NY Doctor of Podiatric Medicine

NPI 1093809949 CMS profile 1248307

111 E 88Th St, New York, NY 10128

Open in the dashboard

General payments

$5,010

85 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Josef Geldwert of New York, NY is reported in the CMS Open Payments database as having received $5,010 across 85 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Podiatrist, Foot Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,176 16
2024 General $627 10
2023 General $601 12
2022 General $1,013 15
2021 General $363 12
2020 General $434 9
2019 General $795 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Josef Geldwert
  • Podiatrist, Foot Surgery median
  • Middle half of Podiatrist, Foot Surgery
  • National median

In program year 2025, general payments to Josef Geldwert were reported at $1,176. Among 732 Podiatrist, Foot Surgery profiles paid that year, the median was $180 and the middle half received between $70 and $569.

Show as a table
Year Josef Geldwert Podiatrist, Foot Surgery median Middle half National median
2019 $795 $167 $67–$484 $163
2020 $434 $114 $40–$323 $114
2021 $363 $171 $57–$502 $132
2022 $1,013 $196 $66–$556 $149
2023 $601 $187 $78–$466 $160
2024 $627 $190 $78–$557 $164
2025 $1,176 $180 $70–$569 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $1,518 15 payments
  2. Treace Medical Concepts, Inc. $593 7 payments
  3. Abbott Laboratories $581 4 payments
  4. Horizon Therapeutics plc $345 6 payments
  5. Bioventus LLC $299 6 payments
  6. GRT US Holding, Inc. $252 6 payments
  7. Ortho Dermatologics, a division of Bausch Health US, LLC $235 8 payments
  8. Amgen Inc. $220 2 payments
  9. Musculoskeletal Transplant Foundation Inc. $198 1 payment
  10. Organogenesis Inc. $174 2 payments
  11. Other $596 28 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,812 84 payments
  2. Travel and Lodging $198 1 payment
Products named General payments · program years 2019–2025
  1. LAPIPLASTY SYSTEM $551 6 payments
  2. PROSTEP MICA $530 5 payments
  3. Supera peripheral stent system $415 3 payments
  4. KRYSTEXXA Krystexxa $293 3 payments
  5. EXOGEN ULTRASOUND BONE HEALING SYSTEM $254 4 payments
  6. Qutenza $252 6 payments
  7. VARIAX $247 2 payments
  8. AUGMENT INJECTABLE $238 2 payments
  9. KRYSTEXXA Inflammation/Rare Disease $220 2 payments
  10. JUBLIA $215 7 payments
  11. Other $3,142 60 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$38,187

Of which drugs: $14

Medicare patients

125

Average age 77

Services billed

500

80 women, 45 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 59%
High blood pressure 55%
Osteoporosis 30%
Ischemic heart disease 26%
Diabetes 23%
Cancer 16%
Depression 16%
Atrial fibrillation 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 13 16 $13

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JUBLIA
  • Ortho Dermatologics, a division of Bausch Health US, LLC $22
$22 — —
NUZYRA
  • Paratek Pharmaceuticals, Inc. $18
$18 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

85 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Foot Surgery in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record